FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      
           
This page is updated frequently with new Kinetics-related patent applications. Subscribe to the Kinetics RSS feed to automatically get the update: related Kinetics RSS feeds. RSS updates for this page: Kinetics RSS RSS


Date/App# patent app List of recent Kinetics-related patents
09/11/14
20140255939
 Nucleic acid-based linkers for detecting and measuring interactions patent thumbnailNucleic acid-based linkers for detecting and measuring interactions
The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics with or without force, detecting analytes, screening aptamers, and encoding/encrypting information. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides.
09/04/14
20140249413
 Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio) patent thumbnailTheranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio)
Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (uspio) in their lysosomes. The amount of uspio loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal.
09/04/14
20140249297
 Antibodies with modified isoelectric points patent thumbnailAntibodies with modified isoelectric points
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
09/04/14
20140249136
 Parenteral formulations of dopamine agonists patent thumbnailParenteral formulations of dopamine agonists
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics..
09/04/14
20140249124
 Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same patent thumbnailPharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
09/04/14
20140248237
 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases patent thumbnailSoluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
08/28/14
20140243340
 Cytochrome p450 oxidase inhibitors and uses thereof patent thumbnailCytochrome p450 oxidase inhibitors and uses thereof
Or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of cyp enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by cyp enzymes..
08/28/14
20140243331
 Inhibitors of inv(16) leukemia patent thumbnailInhibitors of inv(16) leukemia
This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
08/28/14
20140238265
 Product patent thumbnailProduct
A method for manufacturing a cellular geopolymer product, which method comprises the steps: (a) forming an activated geopolymer premix by addition to a geopolymer premix of an activator compound that initiates a condensation reaction in the geopolymer premix; (b) casting the activated geopolymer premix in a desired configuration; and (c) generating gas bubbles in the activated geopolymer premix as the condensation reaction proceeds and the activated geopolymer premix stiffens to produce a self-supporting cellular structure; and (d) curing the self-supporting cellular structure to produce the cellular geopolymer product, wherein in step (c) the characteristics of the activated geopolymer premix and the reaction kinetics of the condensation reaction are controlled to achieve formation of the self-supporting cellular structure.. .
08/21/14
20140236069
 Pharmacokinetics of iontophoretic sumatriptan administration patent thumbnailPharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
08/21/14
20140232029
Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.
08/14/14
20140230080
Method for inducing hepatocellular variation, and production method for chimeric non-human animal having humanized liver
The present invention provides (1) a method for producing a non-human animal having a humanized liver, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, (2) a non-human animal having a humanized liver, produced by the method, (3) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using the animal, (4) a method for producing human hepatocytes, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, and (5) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using human hepatocytes produced by the method.. .
08/07/14
20140221434
Altering pharmacokinetics of pirfenidone therapy
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
08/07/14
20140221433
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
The present invention relates to an improved and shortened synthesis of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions.. .
07/24/14
20140205918
Storage element and method for the production thereof
A storage element for a solid electrolyte battery is provided. The storage element has a main member having a porous matrix of sintered ceramic particles in which particles that are made of a metal and/or a metal oxide and jointly form a redox couple are embedded.
07/24/14
20140205525
Amine promotion for co2 capture
Promoter amines are used to enhance co2 uptake by sterically hindered or tertiary amines. The promoter amines can be cyclic amines, including aromatic cyclic amines or bridged cyclic amines.
07/17/14
20140200547
Method for altering drug pharmacokinetics based on medical delivery platform
A method for directly delivering whereby a substance is introduced into an intradermal space within mammalian skin which involves administering the substance through at least one small gauge hollow needle having an outlet with an exposed height between 0 and 1 mm. The outlet is inserted into the skin to a depth of between 0.3 mm and 2 mm such that the delivery of the substance occurs at a depth between 0.3 mm and 2 mm..
07/10/14
20140193910
Methods for producing pancreatic precursor cells and uses thereof
The present invention is directed to methods for readily propagating somatic pancreatic precursor cells. The methods comprise isolating cells from intact pancreatic samples and enhancing guanine nucleotide (gnp) biosynthesis in cultures comprising these cells, thereby expanding guanine nucleotide pools.
07/10/14
20140193498
Compositions and methods for treating metabolic disorders
Compositions and methods for improving the pharmacokinetics and reducing the risk of adverse events resulting from biguanide compound administration are provided, comprising administering delayed release formulations of such compounds having a lag phase release.. .
07/10/14
20140193320
Use of triphenyl phosphate as risk mitigant for metal amide hydrogen storage materials
A process in a resulting product of the process in which a hydrogen storage metal amide is modified by a ball milling process using an additive of tpp. The resulting product provides for a hydrogen storage metal amide having a coating that renders the hydrogen storage metal amide resistant to air, ambient moisture, and liquid water while improving useful hydrogen storage and release kinetics..
07/10/14
20140192941
Method of acceleration of nuclear transmutation of isotopes by carrying out exothermic reactions
Methods for acceleration of nuclear transmutation of tritium and radioactive isotopes of metals, and decontamination of metals contaminated with radioactive isotopes by destroying radioactive isotopes to a required level of residual radioactive inventory in metals with simultaneous release of thermal energy via stimulating accelerated transmutation with the half-life parameters describing kinetics of radioactive isotope destruction much shorter than their generally accepted half-life. The stimulus is applied to radioactive metals by placing them into a chamber, exposing them to gaseous substances of the group of hydrogen, deuterium, tritium, or a mixture of these isotopes in a molecular hydrogen form for said gaseous substances to be absorbed by the metals, heating the metals to a temperature of at least 200° c.
07/03/14
20140187630
Novel compound and medical use thereof
Provided is a levodopa prodrug that overcomes the problems attributed to the blood kinetics of levodopa such as large number of doses and the incidence of side effects due to frequent dosing. (2s)-2-amino-3-(3,4-bis((2-(benzoyloxy)-2-methylpropanoyl)oxy)phenyl)propanoic acid, a salt thereof, or a solvate thereof is a levodopa prodrug, and provides a flat blood concentration-time profile of levodopa through oral administration, and therefore is useful as a preventive and/or therapeutic agent for parkinson's disease and/or parkinson's syndrome that overcomes the problems associated with pharmaceutical preparations of levodopa..
07/03/14
20140183055
Electrochemically mediated atom transfer radical polymerization
Electrochemical reduction of an exemplary atrp catalyst, c11br2/me6tren, is shown to be an efficient process to mediate and execute an atrp. The onset of polymerization occurs only through passage of a cathodic current achieved under a reductive potential to form cu1br2/me6tren, within the reaction medium.
06/26/14
20140179739
Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
The invention relates to a method of treating attention deficit disorder (add) and attention deficit/hyperactivity disorder (adhd) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein the methylphenidate is present in an amount sufficient to achieve substantially zero order kinetics for delivery to the skin or mucosa of a patient in need thereof over a period of time at least 10 hours.. .
06/26/14
20140175054
Independent radiant gas preheating for precursor disassociation control and gas reaction kinetics in low temperature cvd systems
In one embodiment, a gas distribution assembly includes an injection block having at least one inlet to deliver a precursor gas to a plurality of plenums from at least two gas sources, a perforated plate bounding at least one side of each of the plurality of plenums, at least one radiant energy source positioned within each of the plurality of plenums to provide energy to the precursor gas from one or both of the at least two gas sources and flow an energized gas though openings in the perforated plate and into a chamber, and a variable power source coupled to each of the radiant energy sources positioned within each of the plurality of plenums.. .
06/19/14
20140171457
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/19/14
20140171387
Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
Since a compound represented by formula (i) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and/or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc.
06/19/14
20140171370
Formulations of active agents for sustained release
The present invention provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs..
06/19/14
20140170048
Use of triammonium salt of aurin tricarboxylic acid as risk mitigant for aluminum hydride
A process and a resulting product by process of an aluminum hydride which is modified with by physically combining in a ball milling process an aluminum hydride with a triammonium salt of aurin tricarboxylic acid. The resulting product is an aluminum hydride which is resistant to air, ambient moisture, and liquid water while maintaining useful hydrogen storage and release kinetics..
06/19/14
20140166483
Electrokinetics-assisted sensor
An electrokinetics-assisted sensor for sensing a target material. The sensor may include a microstructure deflectable in response to added mass on its body.
06/12/14
20140163452
Pharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
06/12/14
20140163057
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/12/14
20140162942
Inhibition of cyp3a drug metabolism
The present invention provides methods, pharmaceutical compositions, medicaments, and pharmaceutical kits that employ the use of boceprevir as a cyp3a4/5 inhibitor to improve the pharmacokinetics of therapeutic compounds metabolized by cytochrome p450 3a4/5 (cyp3a4/5) enzymes.. .
06/12/14
20140161860
Implantable polymeric device for sustained release of buprenorphine
The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time.
06/12/14
20140161766
Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-mab dnl complex comprises an igg antibody attached to two ad (anchor domain) moieties and four cytokines, each attached to a ddd (docking and dimerization domain) moiety.
06/05/14
20140155560
Nitrogen containing external donor system for propylene polymerization
The present invention discloses new class of nitrogen containing external donor systems. These donor systems are used in titanium supported on magnesium dichloride pro-catalyst system for polymerization of propylene.
06/05/14
20140154697
Apparatus and method for measuring binding kinetics with a resonating sensor
Apparatus and method for detecting a presence of a subject material in a fluid sample using at least one resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material.
06/05/14
20140151245
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.
06/05/14
20140151244
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.
06/05/14
20140151243
Systems and methods of discriminating between a control sample and a test fluid using capacitance
Methods for distinguishing between an aqueous non-blood sample (e.g., a control solution) and a blood sample are provided herein. In one aspect, the method includes using a test strip in which multiple current transients are measured by a meter electrically connected to an electrochemical test strip.
05/29/14
20140148866
Temperature control system
A method of regulating a setting time of a bone filler material, the method comprising: (a) combining at least two filler material components to form a biocompatible mixture; (b) choosing a setting time for the mixture; and (c) regulating a temperature of the mixture to influence reaction kinetics so that the mixture does not set before the chosen setting time.. .
05/29/14
20140148782
Tissue infusion system and method
An apparatus and corresponding method for providing convection enhanced delivery of bioactive agent to a tissue site. The apparatus involves the use of semipermeable membranes, typically in the form of one or more hollow fibers, together with a source and conduit of solution containing the bioactive agent to be delivered.
05/22/14
20140142406
Guided myocardial substrate characterization and infarct scar location
An apparatus and method for quantifying myocardial kinetics by positioning two sensors on a myocardial substrate site so that one sensor is directly opposing the other along a ventricular wall; tracking a relative displacement between the two sensors; and determining whether there is an infarct based on the tracked relative displacement.. .
05/22/14
20140142096
Fused substituted aminopyrrolidine derivative
A quinolone synthetic antibacterial agent having excellent properties as a medicine is provided, which has strong antibacterial activity not only to gram-negative bacteria but also to gram-positive cocci that have low sensitivity to quinolone antibacterial agents, and which exhibits high safety and excellent pharmacokinetics. A compound represented by the formula (i) or a salt thereof, or a hydrate thereof.
05/22/14
20140142059
Therapeutic substances that modulate genome methylation
Compounds containing nucleic acid bases or their precursors modified by enrichment at specific sites with heavy stable isotopes of elements naturally present at those sites in minute amount are useful for the treatment of diseases characterized by altered gene expression and altered pattern of epigenomic control. These compounds, when used as nutrients or in other medicinal application methods, can alter the dna methylation pattern in a simple way through the well-understood mechanism of kinetic isotope effect (kie).
05/22/14
20140137664
Inexpensive instrument for measuring wave exposure and water velocity
A sea-floor tethered float instrument containing an accelerometer for measuring wave induced water velocity, ocean currents, relative swell kinetics and the like.. .
05/15/14
20140134147
N-terminal derivatisation of proteins with polysaccharides
The present invention relates to methods for producing n-terminal derivatives of proteins in which a polysaccharide, preferably having at least terminal sialic units and preferably consisting essentially only of sialic acid units, is reacted at the n-terminus of a protein or peptide under controlled conditions to produce an n-terminal derivative. The controlled conditions include use of acidic ph for the derivatisation step and a higher ph for purification.
05/08/14
20140128584
Disubstituted maleic anhydrides with altered kinetics of ring closure
We describe anhydride compounds suitable for physiologically labile modification of amine-containing molecules. The described anhydrides form reversible linkages having desirable kinetics for in vivo delivery of biologically active molecules.
05/08/14
20140128345
Vaginal matrices: nanofibers for contraception and prevention of hiv infection
Described are drug delivery systems incorporating electrospun fibers that comprise and deliver physicochemically diverse drug compounds. Such fibers provide significant advantages in drug agent release, such as adaptability for solid dosage delivery to mucosal tissues.
05/08/14
20140127826
Method for measuring binding kinetics with a resonating sensor
Detecting a presence of a subject material in a fluid sample using at least one resonating sensor immersible in the fluid sample. Binding kinetics of an interaction of an analyte material present in the fluid sample are measured with the resonating sensor, which has binding sites for the analyte material.
05/08/14
20140127609
Methods for using novel cathode and electrolyte materials for solid oxide fuel cells and ion transport membranes
Methods using novel cathode, electrolyte and oxygen separation materials operating at intermediate temperatures for use in solid oxide fuel cells and ion transport membranes include oxides with perovskite related structures and an ordered arrangement of a site cations. The materials have significantly faster oxygen kinetics than in corresponding disordered perovskites..
05/01/14
20140117574
Strain and kinetics control during separation phase of imprint process
Systems and methods for improving robust layer separation during the separation process of an imprint lithography process are described. Included are methods of matching strains between a substrate to be imprinted and the template, varying or modifying the forces applied to the template and/or the substrate during separation, or varying or modifying the kinetics of the separation process..
04/24/14
20140113856
Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“edta”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients.
04/24/14
20140112881
Crosslinked polymer nano-assemblies and uses thereof
The invention provides a novel system of nano-assemblies and related method for delivery of therapeutic, diagnostic or imaging agent to biological sites. The compositions and methods of the invention enable the syntheses of novel polymeric nano-assemblies (nanoparticles) under non-emulsion conditions with the incorporation of hydrophobic guest molecules.
04/17/14
20140105889
Method for altering plasma retention and immunogenicity of antigen-binding molecule
The present invention demonstrated that the modification of the fc region of an antigen-binding molecule into an fc region that does not form in a neutral ph range a heterotetramer complex containing two molecules of fcrn and an active fcγ receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response..
04/17/14
20140103215
Terahertz scanning reflectometer
A terahertz scanning reflectometer is described herein. A high sensitivity terahertz scanning reflectometer is used to measure dynamic surface deformation and delamination characteristics in real-time.
04/10/14
20140100292
Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
The present invention relates inter alia to the use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolution kinetics (dissolution) and/or the water loading of tablets.. .
04/10/14
20140100203
Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
An oral dosage form comprising a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed. A method of elevating and sustaining the blood level concentration of 25-hydroxy-vitamin d3 in a human in need thereof comprising orally administering or parenterally administering by injection or infusion, at least once every 7 days, a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days, wherein the single doses orally administered at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.


Popular terms: [SEARCH]

Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



1.0496

3231

3 - 0 - 71